International Assets Investment Management LLC Takes Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

International Assets Investment Management LLC acquired a new stake in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 58,548 shares of the specialty pharmaceutical company’s stock, valued at approximately $7,201,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. ST Germain D J Co. Inc. bought a new position in shares of Jazz Pharmaceuticals during the second quarter valued at about $40,000. Covestor Ltd raised its stake in Jazz Pharmaceuticals by 676.5% in the third quarter. Covestor Ltd now owns 396 shares of the specialty pharmaceutical company’s stock worth $51,000 after buying an additional 345 shares in the last quarter. Spire Wealth Management raised its stake in Jazz Pharmaceuticals by 128.6% in the third quarter. Spire Wealth Management now owns 423 shares of the specialty pharmaceutical company’s stock worth $55,000 after buying an additional 238 shares in the last quarter. Headinvest LLC bought a new position in Jazz Pharmaceuticals in the third quarter worth about $56,000. Finally, Signaturefd LLC raised its stake in Jazz Pharmaceuticals by 85.7% in the third quarter. Signaturefd LLC now owns 546 shares of the specialty pharmaceutical company’s stock worth $71,000 after buying an additional 252 shares in the last quarter. 89.14% of the stock is owned by institutional investors.

Insider Activity at Jazz Pharmaceuticals

In related news, CAO Patricia Carr sold 1,936 shares of the firm’s stock in a transaction that occurred on Wednesday, March 6th. The shares were sold at an average price of $119.64, for a total transaction of $231,623.04. Following the completion of the sale, the chief accounting officer now owns 8,364 shares of the company’s stock, valued at $1,000,668.96. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In related news, CAO Patricia Carr sold 1,936 shares of the firm’s stock in a transaction that occurred on Wednesday, March 6th. The shares were sold at an average price of $119.64, for a total value of $231,623.04. Following the sale, the chief accounting officer now owns 8,364 shares in the company, valued at $1,000,668.96. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Philip L. Johnson bought 12,000 shares of the company’s stock in a transaction that occurred on Friday, March 1st. The stock was bought at an average price of $119.65 per share, for a total transaction of $1,435,800.00. Following the acquisition, the chief financial officer now directly owns 27,932 shares of the company’s stock, valued at approximately $3,342,063.80. The disclosure for this purchase can be found here. 4.40% of the stock is owned by insiders.

Jazz Pharmaceuticals Price Performance

Shares of JAZZ opened at $110.58 on Monday. The company has a market capitalization of $6.97 billion, a P/E ratio of 18.07, a price-to-earnings-growth ratio of 1.53 and a beta of 0.59. The company has a quick ratio of 1.85, a current ratio of 2.24 and a debt-to-equity ratio of 1.37. The firm has a 50 day moving average of $121.21 and a 200 day moving average of $123.09. Jazz Pharmaceuticals plc has a twelve month low of $110.42 and a twelve month high of $147.14.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its quarterly earnings results on Wednesday, February 28th. The specialty pharmaceutical company reported $4.40 earnings per share for the quarter, missing the consensus estimate of $4.44 by ($0.04). The firm had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $1.01 billion. Jazz Pharmaceuticals had a net margin of 10.82% and a return on equity of 31.27%. As a group, equities research analysts anticipate that Jazz Pharmaceuticals plc will post 16.24 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on the stock. Robert W. Baird assumed coverage on shares of Jazz Pharmaceuticals in a research note on Wednesday, January 3rd. They issued an “outperform” rating and a $160.00 price target for the company. HC Wainwright decreased their price target on shares of Jazz Pharmaceuticals from $204.00 to $200.00 and set a “buy” rating for the company in a research note on Thursday, March 14th. Barclays decreased their price target on shares of Jazz Pharmaceuticals from $235.00 to $230.00 and set an “overweight” rating for the company in a research note on Friday, March 1st. Needham & Company LLC reaffirmed a “buy” rating and set a $220.00 target price on shares of Jazz Pharmaceuticals in a research note on Wednesday, March 20th. Finally, Piper Sandler raised their target price on shares of Jazz Pharmaceuticals from $171.00 to $188.00 and gave the company an “overweight” rating in a research note on Wednesday, March 20th. Two research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, Jazz Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $195.08.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.